5 days ago
In an interview with a rodent Stuart Ashman of Skinbiotherapeutics (SBTX) branded me a “prolific liar” without actually evidencing one single lie. Anyhow on the question of prolific liars…
39 days ago
The overpaid Geordie poltroon and prolific teller of his truths who, pro tem, acts as CEO of Skinbiotherapeutics (SBTX) says that he cannot give us any detail about sales to Croda (CRDA) because of NDAs so here is an easy question he can answer….
41 days ago
Bearded Geordie poltroon Stuart Ashman says without citing one actual example that I am a “prolific liar.” The overpaid and under-delivering CEO of Skinbiotherapeutics (SBTX) thinks that he always tells the truth. Let’s rewind to June 16th when shareholders were 10% diluted in a £4.2 million placing.
49 days ago
Stuart Ashman, the incompetent in charge at Skinbiotherapeutics (SBTX) recorded a podcast with the sycophantic poltroon Lemming yesterday in which he made statements which surely AIM Regulation must be all over. This is just not the way a CEO should conduct himself, even if the audience is only 23, as the maths just does not stack up.
51 days ago
I have now written to both regulators demanding a full enquiry into Stuart Ashman and Skin biotherapeutics (SBTX) as , at the very least , they have broken AIM Rule 10 at worse they have done a placing at a false price because of non disclosure to the wider market of adverse trading performance. In the wake of December 5 prelims there now needs to be a full formal enquiry
52 days ago
Laughably Stuart Ashman of Skinbiotherpeutics (SBTX) yesterday praised his bean counter Emily Bertram for her good work and said she’d be promoted for that good work (ching ching for young Emily) in January. This came on a day when June 2025 results finally emerged and contain two material breaches of IFRS. And Emily is being praised and rewarded for her blunders? I have written to my good pals at the FRC…
52 days ago
Skinbiotherapeutics (SBTX) published its final audited results for the twelve months to 30 June 2025 yesterday. FTSE 100 Companies operating across the world with billions of pounds of sales get their numbers out within three months. Skins took almost twice as long despite having just seven, all UK based, subsidiaries and 34 employees.
81 days ago
A, normally sensible, reader pings in his theory as to why shares in Skinbiotherapeutics (SBTX) are off by 12% today at 15.375p. He writes:
85 days ago
Our in house bien pensant PL appears to have stumbled on forecasts from credible tier 1 brokers for how much revenue Croda (CRDA) will make from sales of the Skinbiotherapeutics (SBTX) product Zenakine. The source of this is, PL says, AI so it may be hogwash but it, perhaps, raises two critical points.
86 days ago
In an attempt to polish the turd which was the failure of Skinbiotherapeutics (SBTX) to ‘fess that it would miss revenue forecasts for the year to June 30 2025 by a country mile before doing a placing on 16 June, comrade Lemming makes an excuse in the comments section on this website which fails to appreciate IFRS Revenue recognition Rules.
160 days ago
A helpful reader supplies a video of a man that certain commentators, habitually resident a long way up a Tyneside rectum, say that I really should respect and not refer to as the bearded, troughing, useless Geordie poltroon. That is to say Skinbiotherapeutics (SBTX) CEO Stuart Ashman. In it he discusses the forecasts published on July 7 by Singer analyst Karl “Kevin” Keegan.
166 days ago
I just cannot see how Skinbiotherapeutics (SBTX) did not lead investors up the garden path, by omission not act, ahead of the June 16 2025 placing raising £4.2 million at 17p. Heads really should roll and if Nomad Singer is too weak to act against disgraced CEO Stuart Ashman and the company I have written to both the FCA and the Oxymorons at AIM Regulation asking for an immediate enquiry.
167 days ago
Skinbiotherapeutics (SBTX) later than expected trading update has been poorly received by investors: its not only a revenue miss but howling schoolboy errors by the new FD. This is another management clusterfuck and I shall elaborate n that in a bearcast special shortly.
174 days ago
I do not disagree with a word in this email. I have also made my views clear to the regulators. It is abundantly clear that forecasts out there are wrong and that the company and ts house broker knows all about it and is happy to see a false market continue. The reader writes:
182 days ago
One will disappoint the conspiracy theorists the other is very good news indeed for Skinbiotherapeutics (SBTX). First for the folks with green biros. Croda stated in the results day analyst briefing:
184 days ago
https://shareprophets.com/81596
190 days ago
I am not sure what the prize will be but there will be one. Stuart Ashman has said that the research from analyst “Kevin” Keegan at house broker Singer contain errors and we all know the sales numbers are just plain wrong. I will explain my forecasts for the years ending June 30 2025 and 2026 below. The contest is to give your 2026 forecast and as a tie breaker 2025.
193 days ago
I am off to see an entrance to the Underworld. Ahead of that a few words on a matter which is making some folks go mad, the Croda (CRDA) NDA with Skinbiotherapeutics (SBTX)
202 days ago
The Singer’s initiation note on its corporate client Skinbotherapeutics(SBTX) is a curious piece of fish. For staters Singer’s makes it clear that it will not, under any circumstances, be made available to private investors it is for II’s and City HNWIs only. This is pointless.
230 days ago
274 days ago
Yes, I still think that shares in Skinbiotherapeutics (SBTX) are cheap at 19p, that there will be three quarters of revenues from Croda booked in the year to June 30 2025 with two quarters fully paid. But I see that the shares are off a penny today because we know what is looming.
279 days ago
Folks like the Lemming thought that Skinbiotherapeutics (SBTX) FD Manprick Randhawa was the bees knees and were jolly cross with me for rebranding him for his patent incompetence. In my view he was useless, unable to communicate with serious investors or to stop Stuart Ashman abusing the word accretive and, at least, partially responsible for the cack handed and dilutive financing of two acquisitions. He was unable to control costs. Well, today, he has gone to pursue other business interests. Great news.. It has prompted me to buy more shares, increasing my holding by 25%.
279 days ago
In today's podcast I look at Croda (CRDA) and Skinbiotherapeutics (SBTX), V22, Avacta (AVCT), the biggest threat to your wealth and it is not what Gary Newman et al are foaming at the mouth about, at Cleantech Lithium (CTL) and the disgrace at Anexo (ANX)
280 days ago
Croda (CRDA) has a trading statement out today and the Skinbiotherapeutics (SBTX) obsessives are looking at how revenues from consumer care leapt by £18 million, Quarter on Quarter, to £255 million in Q1 2025. Natch they speculate as to how much of this is Skins related, bearing in mind that Skins would get a double digit margin on whatever is sold. I reckon the answer is “norra lot” but such speculation has pushed the shares up to 25.5p. Now here is my guess for the next RNS!
284 days ago
I discuss why the former is not, I believe a threat and why Optibiotix (OPTI) shares are so cheap and on the latter I comment on the idea that Croda (CRDA) might launch a cheeky 50p a share bid for Skinbiotherapeutics (SBTX). FWIW I think its unlikely although stranger things happen at sea.
294 days ago
309 days ago
323 days ago
336 days ago
344 days ago
I start with an observation ( supportive) and a question about Tesco (TSCO). then a few thoughts on why interest rate cuts will not necessarily drive growth. Then Skinbiotherapeutics (SBTX) and its Croda NDA. Finally, prompted by PL, what makes a strong shareholder list?
414 days ago
Skinbiotherapeutics (SBTX) is very simple. If you believe that Croda could deliver £25 million GP or anywhere close to that as CEO Stuart Ashman has intimated the shares are stupendously cheap at 17.75p. Ashman needs to do nothing apart from deliver other corporate deals and more GP from his existing IP and no more shares need be issued. Hell’s teeth why issue shares now or indeed at twice or three times the price given that on Ashman’s Croda numbers the shares could easily be 100p or even 200p! But Ashman is a git.
423 days ago
I wonder why shares in SkinBiotherapeutics (SBTX) have not raced ahead more on the news from Croda. One possible explanation put to me by Lemming investor is that Optibiotix (OPTI) has been reducing its holding which was last stated at 10.92%.
979 days ago
SkinBioTherapeutics (SBTX) has announced on its AxisBiotix-Ps (psoriasis) product that it has commenced sales in Spain aided by the launch of a regional website and on its skin care active ingredient SkinBiotix that partner, cosmetics business of FTSE-100 Croda (CRDA), Sederma has noted ‘exciting’ additional benefits which means delays in monetisation. Is that good news or bad?
1620 days ago
SkinBioTherapeutics (SBTX) has delivered a “Business Update” including that the commercial launch of AxisBiotix-Ps is on track for Q4 and has further encouraging potential, that SkinBiotix manufacturing scale-up with Croda (CRDA) is progressing to schedule and 30th June year-end cash totalled £4.6 million. Sounds good.
